In vitro Anti-HIV Potency of Stampidine Alone and in Combination with Standard Anti-HIV Drugs

Summary The purpose of the present study was to compare the in vitro anti-HIV potency of stampidine (CAS 217178-62-6), a novel aryl phosphate derivative of stavudine (CAS 3056-17-5), and drug combinations containing stampidine to the anti-HIV potency of the standard drugs zidovudine (CAS 30516-87-1), stavudine, lamivudine (CAS 134678-17-4), nelfinavir (CAS 159989-65-8), and nevirapine (CAS 129618-40-2) as well as their combinations. Stampidine inhibited the laboratory HIV-1 strain HTLVIIIB (B-envelope subtype) as well as the primary clinical HIV-1 isolates BR/92/025 (C-envelope subtype) and BR/93/20 (F-envelope subtype) with subnanomolar IC50 values. Stampidine was as effective as zidovudine against HTLVIIIB and BR/92/025 and 3-logs more effective than zidovudine against BR/93/20. Stampidine was more effective than stavudine, lamivudine, nel-finavir, and nevirapine against all three HIV-1 isolates. The combination of stampidine with zidovudine + lamivudine was more effective than the combination of nelfinavir or nevirapine with zidovudine + lamivudine against all three HIV-1 isolates. The combination of stampidine with nelfinavir was more effective than zidovudine + lamivudine as well as the combination of zidovudine + lamivudine with nelfinavir. The combination of stampidine with lamivudine + nelfinavir was more effective than the combination of zidovudine with lamivudine + nelfinavir. The combination of stampidine with lamivudine + nevirapine was more effective than the combination of stavudine with lamivudine + nevirapine. These findings demonstrate that (a) stampidine, as well as its combinations with the standard anti-HIV drugs zidovudine, lamivudine, nelfinavir or nevirapine, are potent inhibitors of HIV-1 replication in human peripheral blood mononuclear cells, and (b) replacement of either zidovudine, zidovudine+lamivudine or stavudine in 3-drug cocktails with stampidine resulted in greater anti-HIV potency in vitro.

[1]  F. Uckun,et al.  Stampidine is a potential nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. , 2004, Fertility and sterility.

[2]  F. Uckun,et al.  In vitro Activity of Stampidine against Primary Clinical Human Immunodeficiency Virus Isolates , 2004, Arzneimittelforschung.

[3]  F. Uckun,et al.  Toxicity and Pharmacokinetics of Stampidine in Mice and Rats , 2003, Arzneimittelforschung.

[4]  F. Uckun,et al.  In Vivo Antiretroviral Activity of Stampidine in Chronically Feline Immunodeficiency Virus-Infected Cats , 2003, Antimicrobial Agents and Chemotherapy.

[5]  F. Uckun,et al.  In Vivo Toxicity, Pharmacokinetics, and Anti-Human Immunodeficiency Virus Activity of Stavudine-5′-(p-Bromophenyl Methoxyalaninyl Phosphate) (Stampidine) in Mice , 2002, Antimicrobial Agents and Chemotherapy.

[6]  D. Richman,et al.  Stampidine Is a Potent Inhibitor of Zidovudine- and Nucleoside Analog Reverse Transcriptase Inhibitor-Resistant Primary Clinical Human Immunodeficiency Virus Type 1 Isolates with Thymidine Analog Mutations , 2002, Antimicrobial Agents and Chemotherapy.

[7]  P. Mercié,et al.  [AIDS--the first 20 years]. , 2001, La Revue de medecine interne.

[8]  F. Clavel,et al.  Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. , 2001, The Journal of infectious diseases.

[9]  D. Cooper,et al.  Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine. , 2001, AIDS research and human retroviruses.

[10]  J. Lang,et al.  Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. , 2001, Journal of acquired immune deficiency syndromes.

[11]  J. Cherrington,et al.  Adefovir and Tenofovir Susceptibilities of HIV‐1 After 24 to 48 Weeks of Adefovir Dipivoxil Therapy: Genotypic and Phenotypic Analyses of Study GS‐96‐408 , 2001, Journal of acquired immune deficiency syndromes.

[12]  N. Graham,et al.  Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. , 2001, AIDS research and human retroviruses.

[13]  D. Katzenstein,et al.  Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. , 2001, Journal of acquired immune deficiency syndromes.

[14]  M. Gottlieb.  AIDS--past and future. , 2001, The New England journal of medicine.

[15]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[16]  B. Schmidt,et al.  Frequency of Genotypic and Phenotypic Drug‐Resistant HIV‐1 Among Therapy‐Naive Patients of the German Seroconverter Study , 2001, Journal of acquired immune deficiency syndromes.

[17]  M. Peeters,et al.  Patterns of Resistance Mutations to Antiretroviral Drugs in Extensively Treated HIV‐1‐Infected Patients With Failure of Highly Active Antiretroviral Therapy , 2001, Journal of acquired immune deficiency syndromes.

[18]  Douglas D. Richman,et al.  HIV chemotherapy , 2001, Nature.

[19]  C. Briones,et al.  Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. , 2000, AIDS.

[20]  D. Richman,et al.  Incidence and impact of resistance against approved antiretroviral drugs , 2000, Reviews in medical virology.

[21]  W. O'brien,et al.  Resistance against reverse transcriptase inhibitors. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Bilello,et al.  The Triple Combination Indinavir-Zidovudine-Lamivudine Is Highly Synergistic , 2000, Antimicrobial Agents and Chemotherapy.

[23]  M. Lederman,et al.  Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. , 2000, The Journal of infectious diseases.

[24]  C. Katlama,et al.  HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy , 2000, AIDS.

[25]  S. Hammer,et al.  Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine , 2000, AIDS (London).

[26]  J. Moltó,et al.  [Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy]. , 2000, Medicina clinica.

[27]  M. Gersten,et al.  Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. , 1999, The New England journal of medicine.

[28]  P. Massip,et al.  Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine , 1999, Journal of medical virology.

[29]  T. Merigan,et al.  Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. , 1999, AIDS.

[30]  M. Zazzi,et al.  Genotypic Resistance to Zidovudine as a Predictor of Failure of Subsequent Therapy with Human Immunodeficiency Virus Type-1 Nucleoside Reverse-Transcriptase Inhibitors , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[31]  Gerhard Müller,et al.  CombiTool - A New Computer Program for Analyzing Combination Experiments with Biologically Active Agents , 1999, Comput. Biomed. Res..

[32]  R. Shafer,et al.  Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[33]  V. Calvez,et al.  Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy , 1999, Antiviral therapy.

[34]  F. Uckun,et al.  Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives. , 1998, Bioorganic & medicinal chemistry letters.

[35]  F. Uckun,et al.  TXU (Anti-CD7)-Pokeweed Antiviral Protein as a Potent Inhibitor of Human Immunodeficiency Virus , 1998, Antimicrobial Agents and Chemotherapy.

[36]  F. Uckun,et al.  D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] as a potent and non-toxic anti-human immunodeficiency virus agent. , 1998, Antiviral chemistry & chemotherapy.

[37]  M. Dudley,et al.  Clinical Pharmacokinetics of Stavudine , 1997, Clinical pharmacokinetics.

[38]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[39]  V. Johnson.  Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. , 1995, The Journal of infectious diseases.

[40]  H. Balfour,et al.  Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein , 1993, Antimicrobial Agents and Chemotherapy.